Compliance Radar
Who was sanctioned, and for what?
Fines, court rulings and incidents from Europe, North America, Latin America and Asia-Pacific: 1,869 cases from 39 jurisdictions, each with an official source and checked against that source before publication. Filter by country, area of law and sector. Click a chart to drill down one level.
Click a bar to drill down one level.
Where?
by regionAll jurisdictions
What for?
by area of lawAll areas of law
Who?
by company- Purdue Pharma L.P. €4.75bn 78 % · 1 case
- Teva Pharmaceutical Industries (Teva-Gruppe) €462.6m 8 % · 1 case
- Teva Pharmaceuticals USA, Inc. und Teva Neuroscience, Inc. €411.6m 7 % · 1 case
- Gilead Sciences, Inc. €177.8m 3 % · 1 case
- Pfizer Inc. (für die Tochter Biohaven Pharmaceutical Holding Company Ltd.) €57.1m 1 % · 1 case
- Anonymised companies €49.1m 1 % · 4 cases
- Novamont S.p.A., Eni S.p.A. €32.1m 1 % · 1 case
- Dompé U.S. Inc. €27.5m 0 % · 1 case
- Vifor Pharma UK Limited u. a. (CSL-Konzern) €27.4m 0 % · 1 case
- The Chemours Company; The Chemours Company FC, LLC €19.8m 0 % · 1 case
- 24 more€44.3m
When?
per quarter, by date of decision| Period | Cases | Total |
|---|---|---|
| Q4 2023 | 0 | – |
| Q1 2024 | 0 | – |
| Q2 2024 | 0 | – |
| Q3 2024 | 0 | – |
| Q4 2024 | 0 | – |
| Q1 2025 | 0 | – |
| Q2 2025 | 1 | €27.4m |
| Q3 2025 | 0 | – |
| Q4 2025 | 0 | – |
| Q1 2026 | 0 | – |
| Q2 2026 | 0 | – |
| Q3 2026 | 0 | – |
| Q4 2026 | 0 | – |
1 case
23 May 2025 Vifor Pharma UK Limited u. a. (CSL-Konzern)CMA: Vifor pays GBP 23m to the NHS after suspected disparagement of a rival €27.4m
The CMA had investigated whether, between 2010 and 2024, Vifor abused a suspected dominant position in high-dose intravenous iron by spreading potentially misleading claims about the safety of the rival product Monofer compared with its own Ferinject. It accepted binding commitments: a voluntary payment of GBP 23m to the NHS, a corrective communication campaign aimed at healthcare professionals and additional compliance measures; no infringement was found.
Safety claims about competing products made to healthcare professionals must be substantiated and balanced – disparagement can be pursued as an abuse of market power.
Claims about competitor products in pharmaceutical marketing
- Authority / court
- Competition and Markets Authority (CMA)
- Area of law
- Competition law · Abuse of market power
- Legal basis
- Chapter II prohibition, section 18(1) Competition Act 1998 (Verdacht); Verpflichtungszusagen nach section 31A Competition Act 1998
- Action
- Other
- Status of proceedings
- final
- Sector
- Chemicals and pharmaceuticals
- Published
- 23 May 2025
Original amount 23,000,000 GBP, converted at the ECB reference rate of 23 May 2025.
- CMA case page: Investigation into suspected anti-competitive conduct by Vifor Pharma in relation to intravenous iron treatments Enforcement database of an authority
- CMA: Decision to accept commitments offered by Vifor in relation to the supply of high-dose intravenous iron, Case 51377 (23 May 2025) Decision of an authority
Checked against the official source on 3 Oct 2026 · Direct link